Abstract is public from SNO26 yesterday. Tighter numbers confirmed: 93.5% agreement with MRI overall, 83.9% on previously treated lesions, solid quantitative match, ~86% sensitivity, and very mild side effects in only ~16% of patients. Full data expected later this year.
$RADX
2
3
168
Now RBC, Oppenheimer, Mizuho and Wedbush lowered their PT for Corbus. The new avarage PT is 30.75$, all keep the Outperform rating. Down 18,5% at the moment,3.25$, late breaking oral presentation this weekend at ObesityWeek26 coming up.
Said I would not buy more but I..
$CRBP
1
186




